patients with a known history of a seizure disorder or underlying
hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes,
or hypercoagulable disorders).
-- In some female patients, menses have resumed following PROCRIT therapy;
the possibility of pregnancy should be discussed and the need for
-- Prior to and regularly during PROCRIT therapy monitor iron status;
transferrin saturation should be greater than or equal to 20% and
ferritin should be greater than or equal to 100 ng/mL. During therapy
absolute or functional iron deficiency may develop and all patients
will eventually require supplemental iron to adequately support
erythropoiesis stimulated by PROCRIT.
-- In studies, the most common side effects included fever (pyrexia),
diarrhea, nausea, vomiting, swelling of hands or feet (edema), lack or
loss of strength or weakness (asthenia, fatigue), shortness of breath,
high blood pressure, headache, joint pain (arthralgias), abnormal skin
sensations (as tingling or tickling or itching or burning;
paresthesia), rash, constipation, and upper respiratory infection.
Please visit http://www.procrit.com for the full Prescribing Information, including the Boxed Warning.
About Ortho Biotech Products, L.P.
Ortho Biotech Products, L.P. is a leading biopharmaceutical company
devoted to helping improve the lives of patients with cancer and with
anemia due to multiple causes, including chronic kidney disease. Since it
was founded in 1990, Ortho Biotech and its worldwide affiliates have earned
a global reputation for researching, manufacturing and marketing innovative
products that enhance patients' health. Located in Bridgewater, N.J., Ortho
|SOURCE Ortho Biotech Products, L.P.|
Copyright©2007 PR Newswire.
All rights reserved